Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency

Abstract

Deficiency of adenosine deaminase 2 (ADA2) due to homozygous or compound heterozygous mutations in the cat eye syndrome chromosome region, candidate 1 (CECR1) gene causes an autoimmune phenotype with systemic vasculitis affecting the skin, inner organs, and the central nervous system. Typically, stroke has been reported to follow systemic inflammatory disease and predominantly affects posterior and central brain areas. Here, we describe one of the rare patients in whom acute mesencephalic stroke preceded systemic inflammation and presented as initial clinical symptom. Symptoms typical for ADA2 deficiency such as fever, livedo racemosa, abdominal colics, arthralgias, and Raynaud phenomenon were observed later. Moreover, angiography of cerebral arteries did not reveal typical vasculitic findings supporting the hypothesis that alternative mechanism of vascular occlusion might have caused the stroke. ADA2 deficiency should be considered in patients with childhood stroke despite the absence of systemic inflammation and cerebral vasculitis.

Keywords

stroke - adenosine deaminase 2 deficiency - CECR1 - polyarteritis nodosa - vasculitis - Sneddon syndrome

• References

• 1 Navon Elkan P, Pierce SB, Segel R , et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370 (10) 921-931
• 2 Zhou Q, Yang D, Ombrello AK , et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370 (10) 911-920
• 3 Bras J, Guerreiro R, Santo GC. Mutant ADA2 in vasculopathies. N Engl J Med 2014; 371 (5) 478-480
• 4 Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180-185
• 5 Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J 2016; 14 (1) 51
• 6 Hershfield M, Adenosine Deaminase Deficiency. In: Pagon RA, Adam MP, Ardinger HH. , et al, eds. Seattle, WA: GeneReviews; 1993. –2016
• 7 Van Montfrans JM, Hartman EA, Braun KP , et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 2016; 55 (5) 902-910
• 8 Garg N, Kasapcopur O, Foster II J , et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 2014; 173 (6) 827-830
• 9 Twilt M, Benseler SM. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol 2011; 8 (2) 97-107
• 10 Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD, Braun KP. Unexplained early-onset lacunar stroke and inflammatory skin lesions: Consider ADA2 deficiency. Neurology 2015; 84 (20) 2092-2093
• 11 Kaljas Y, Liu C, Skaldin M , et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells. Cell Mol Life Sci 2016;
• 12 Van Eyck L, Liston A, Meyts I. Mutant ADA2 in vasculopathies. N Engl J Med 2014; 371 (5) 478-479
• 13 Belot A, Wassmer E, Twilt M , et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J 2014; 12: 44
• 14 Nanthapisal S, Murphy C, Omoyinmi E , et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 2016; 68 (9) 2314-2322
• 15 van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med 2014; 371 (5) 478